

David C Young

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7649315/publications.pdf>

Version: 2024-02-01

21
papers

457
citations

623188

14
h-index

713013

21
g-index

21
all docs

21
docs citations

21
times ranked

477
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimization of anti- <i>Pseudomonas</i> antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. <i>Pediatric Pulmonology</i> , 2013, 48, 1047-1061.	1.0	51
2	Optimization of anti- <i>Pseudomonas</i> antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins. <i>Pediatric Pulmonology</i> , 2013, 48, 107-122.	1.0	46
3	Population Pharmacokinetics of Intermittent Vancomycin in Children with Cystic Fibrosis. <i>Pharmacotherapy</i> , 2013, 33, 1288-1296.	1.2	41
4	A survey of the utilization of anti- <i>Pseudomonas</i> beta-lactam therapy in cystic fibrosis patients. <i>Pediatric Pulmonology</i> , 2011, 46, 987-990.	1.0	39
5	Utilization of antibiotics for methicillin-resistant <i>Staphylococcus aureus</i> infection in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2015, 50, 552-559.	1.0	39
6	Optimization of anti- <i>Pseudomonas</i> antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. <i>Pediatric Pulmonology</i> , 2012, 47, 1147-1158.	1.0	35
7	Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 339-343.	0.3	35
8	Optimization of anti- <i>Pseudomonas</i> antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. <i>Pediatric Pulmonology</i> , 2013, 48, 211-220.	1.0	32
9	Optimization of anti- <i>Pseudomonas</i> antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary. <i>Pediatric Pulmonology</i> , 2013, 48, 525-537.	1.0	27
10	Patients and families experience with pharmacist care at cystic fibrosis foundation accredited clinics. <i>Pediatric Pulmonology</i> , 2019, 54, 1216-1224.	1.0	16
11	Optimization of anti- <i>Pseudomonas</i> antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium. <i>Pediatric Pulmonology</i> , 2013, 48, 1-7.	1.0	15
12	Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	15
13	An Evaluation of Vancomycin Area Under the Curve Estimation Methods for Children Treated for Acute Pulmonary Exacerbations of Cystic Fibrosis Due to Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Journal of Clinical Pharmacology</i> , 2019, 59, 198-205.	1.0	15
14	State of the art in cystic fibrosis pharmacology—Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) antibiotics. <i>Pediatric Pulmonology</i> , 2020, 55, 33-57.	1.0	14
15	Understanding the expanding role of pharmacy services in outpatient cystic fibrosis care. <i>Pediatric Pulmonology</i> , 2021, 56, 1378-1385.	1.0	9
16	Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: II. Therapies for allergic bronchopulmonary aspergillosis. <i>Pediatric Pulmonology</i> , 2020, 55, 3541-3572.	1.0	8
17	Optimization of anti- <i>Pseudomonas</i> antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins update. <i>Pediatric Pulmonology</i> , 2017, 52, 863-865.	1.0	5
18	State of the art in cystic fibrosis pharmacology optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: III. Executive summary. <i>Pediatric Pulmonology</i> , 2021, 56, 1825-1837.	1.0	5

#	ARTICLE	IF	CITATIONS
19	Survey of current treatment practices for venous thromboembolism in patients with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2020, 55, 149-155.	1.0	4
20	Pharmacokinetics of intermittent dosed intravenous vancomycin in adult persons with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2022, 57, 2646-2651.	1.0	4
21	The indispensable role of pharmacy services and medication therapy management in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2022, 57, .	1.0	2